What is the recommended silodosin tablet dosage for adult men with benign prostatic hyperplasia, and how should it be adjusted in renal or hepatic impairment?

Silodosin Tablet Dosage

The standard dose of silodosin is 8 mg once daily taken with a meal, reduced to 4 mg once daily in patients with moderate renal impairment (creatinine clearance 30-50 mL/min), and contraindicated in severe renal or hepatic impairment. 1

Standard Dosing

• 8 mg once daily with a meal is the recommended dose for adult men with benign prostatic hyperplasia (BPH) and normal renal/hepatic function 1
• Taking silodosin with food is essential to reduce the risk of adverse events, as food intake decreases maximum plasma concentration by 18-43% but was the standard administration method in all clinical trials 1
• This dosing regimen has demonstrated significant improvement in International Prostate Symptom Score (IPSS) and urinary flow rates in multiple phase III trials 2

Renal Impairment Adjustments

Moderate renal impairment (CrCl 30-50 mL/min):

• Reduce dose to 4 mg once daily 1
• Plasma concentrations are approximately three times higher in moderate renal impairment compared to normal function 1
• Exercise caution and monitor patients closely for adverse events 1

Severe renal impairment (CrCl <30 mL/min):

• Silodosin is contraindicated - do not prescribe 1
• The drug has not been studied in this population 1

Hepatic Impairment Adjustments

Mild to moderate hepatic impairment (Child-Pugh scores 7-9):

• No dose adjustment required 1
• Single-dose pharmacokinetics were not significantly altered in moderate hepatic impairment 1

Severe hepatic impairment (Child-Pugh score >10):

• Silodosin is contraindicated - do not prescribe 1
• The drug has not been studied in this population 1

Clinical Efficacy by Dose

Research evidence supports that the 8 mg dose provides superior efficacy in patients with severe lower urinary tract symptoms (IPSS ≥20), while 4 mg may be adequate for moderate symptoms (IPSS 8-19) 3, 4:

• In patients with moderate LUTS, 4 mg and 8 mg showed similar effectiveness 3
• In patients with severe LUTS, 8 mg was significantly better than 4 mg for improving total IPSS, voiding subscore, and quality of life (p = 0.015,0.030, <0.001 respectively) 3
• However, adverse events occurred more frequently with 8 mg versus 4 mg (p = 0.024) 3

Important Contraindications and Drug Interactions

Absolute contraindications 1:

• Concomitant use with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole, ritonavir)
• History of hypersensitivity to silodosin or its ingredients
• Severe renal or hepatic impairment (as noted above)

Not recommended 1:

• Concomitant use with strong P-glycoprotein inhibitors (e.g., cyclosporine) may increase plasma silodosin concentrations
• Combination with other alpha-blockers has not been studied and is not recommended

Key Safety Considerations

Orthostatic hypotension risk increases with age 1:

• Reported in 2.3% of patients <65 years
• 2.9% in patients ≥65 years
• 5.0% in patients ≥75 years

Most common adverse effect 1, 5:

• Retrograde ejaculation occurs in approximately 28% of patients
• However, only 2.8% discontinue treatment due to this effect 5
• This is a class effect of highly selective α1A-adrenoceptor antagonists 6

Intraoperative Floppy Iris Syndrome (IFIS) 2:

• Patients planning cataract surgery must inform their ophthalmologist they are taking silodosin
• This is a recognized complication with all alpha-blockers

Long-term Efficacy

Silodosin provides sustained relief of BPH symptoms for up to 2 years, though efficacy may diminish in patients with larger prostates (>40 mL) 7:

• In prostates <40 mL: IPSS improved 44.3%, BOOI improved 43.5% at 24 months 7
• In prostates ≥40 mL: IPSS improved only 22.6%, BOOI improved 21.1% at 24 months 7
• Dropout rates due to insufficient effects were significantly higher in the large prostate group (20% versus 8.6%) 7